

Fig. 4 – TGF-beta and HGF expression in fetal liver. (A) Expression of *Tgfb1*, *Tgfb2*, *Tgfb3* and *Hgf* was examined in fetal liver samples at 12.5 and 14.5 dpc. *Tgfb1* was highly expressed at both stages. **(B)** TGF-beta-1 protein was detected by Western blot analysis of fetal liver at 12.5 dpc. **(C)** Expression of *Tgfb1* and *Tgfb2*, which encodes its receptor, and *Hgf* and *Met*, which encodes its receptor, was examined by real-time PCR in hepatoblasts, sinusoid endothelial cells and hematopoietic cells according to gates defined in Fig. 3C. *Tgfb1* was predominantly expressed in sinusoid endothelial cells and hematopoietic cells, whereas *Tgfb2* was highly expressed both in sinusoid endothelial cells and hepatoblasts. Both *Hgf* and *Met* were highly expressed in hepatoblasts. **(D)** TGF-beta-1 expression was examined by Western blot analysis in each fraction of cells sorted from ICR mouse fetal liver at 12.5 dpc according to gate settings defined in Fig. 3C. Protein expression levels were normalized to Beta-actin and displayed as intensity per mm².

anti-TGF-beta-1 blocking antibody (Fig. S3). As shown in Fig. S4, some DLK-1 positive and negative cells were stained with anti-phosphorylated SMAD3 Ab in fetal liver at 10.5 dpc. Taken together, it is likely that TGF-beta-1 signaling in both hepatoblasts expressing DLK-1 and non-hepatoblasts was down-regulated after administration of anti-TGF-beta-1 blocking antibody.

To further investigate how TGF-beta-1 controls ECM production in hepatoblasts, we sorted hepatoblasts expressing DLK-1 and cultured them in the presence of TGF-beta-1. After 6 h of culture, *Vtn*, *Fn1* and *Tnc* expression was up-regulated

(Fig. 5D). Taken together, these data strongly suggest that TGF-beta-1/TGFR-2 signaling promotes ECM production by hepatoblasts in fetal liver.

4. Discussion

Hepatoblasts were originally regarded as common progenitors of hepatocytes and biliary epithelial cells and thought to support liver construction through formation of a mesh-like structure (Tanimizu et al., 2003; Sasaki and Sonoda, 2000). Recently, it was reported that expression of SCF and EPO by




Fig. 5 – Functional analysis of the effect of TGF-beta-1/TGFR2 signaling on ECM production in fetal liver. (A) A TGF-beta receptor type-1 Kinase Inhibitor (inhibitor 1) was administered to ICR mouse embryos at 10.25 dpc by intra-cardiac injection, and embryos were then cultured in a whole embryo culture system. Left and right bars show control (DMSO injection) and sample (inhibitor injection) responses, respectively. Expression of *Vtn*, *Fn1* and *Tnc* genes was slightly down-regulated after 6 h and then more significantly so at 12 h of whole embryo culture compared to controls. **(B)** TGF-beta receptor type-1 Kinase Inhibitor II (inhibitor 2) was administered as in (A). Expression of *Vtn*, *Fn1* and *Tnc* was slightly and then significantly down-regulated relative to controls after 6 and 12 h of whole embryo culture, respectively. **(C)** Anti-TGF-beta-1 blocking antibody was administered as in (A). Left and right bars show control (Isotype IgG injection) and sample (blocking antibody injection), respectively. Expression of *Vtn*, *Fn1* and *Tnc* was down-regulated after 12 h of whole embryo culture. **(D)** Hepatoblasts expressing DLK-1 were sorted from 12.5 dpc fetal liver by flow cytometry and 10,000 cells were cultured with or without TGF-beta-1 (10 ng/mL). *Vtn*, *Fn1* and *Tnc* expression was up-regulated after 6 h of *in vitro* culture with TGF-beta-1.

hepatoblasts promotes HSC expansion and differentiation (Lodish et al., 2010; Sugiyama et al., 2011). ECMs act together with cytokines to maximize cytokine signaling in specific tissues (Hynes and Yamada, 1982; Humphries et al., 1989; Frisch and Ruoslahti, 1997; Taipale and Keski-Oja, 1997).

Based on integrin expression patterns, we hypothesized that their binding partners were ECM proteins. Following comparison of *integrin-alpha* in each hematopoietic cell fraction, we found that *Itga4* and *Itga6* are highly expressed in HSC and BFU-E fractions. It is reported that Integrin alpha-4 accelerates erythroid cell differentiation but does not affect HSC colonization in fetal liver (Yanai et al., 1994; Arroyo et al., 1999). Our data suggest that regulation of erythroid cell differentiation through Integrin alpha-4 occurs primarily at the level of HSCs and BFU-E in fetal liver. We found that *Itga5*, *Itga9* and *ItgaV* were moderately expressed in HSC and BFU-E fractions. Since hematopoietic cells derived from *Itga5*, *Itga9* or *ItgaV* single knockout mice can colonize fetal liver, it is likely that only Integrin beta-1 is specifically required for hematopoietic cell colonization of fetal liver and that various Integrin alpha can substitute for each other to some extent (Taverna et al., 1998; Bader et al., 1998; Huang et al., 2000). In fetal liver, *Vtn* was highly expressed among several ECM genes at both 12.5 and 14.5 dpc, and Vitronectin protein was detected at high levels in hepatoblasts at 12.5 dpc. *Vtn*-deficient mouse embryos reportedly show no abnormalities (Zheng et al., 1995), suggesting that other ECM factors compensate for its loss. On the other hand, *fibronectin*-deficient mice die early in embryogenesis probably due to abnormal mesoderm development (George et al., 1993). Fibronectin binds to Integrins alpha-4/beta-1, alpha-5/beta-1 and alpha-V/beta-1. These results and our gene expression data suggest that Integrin alpha-4/beta-1 and Fibronectin signaling is likely important for HSC differentiation.

Among cells comprising the fetal liver, hepatoblasts predominantly produce ECM factors. Here, we evaluated mouse embryos lacking *Map2k4*^{-/-}, the gene encoding the dual specificity mitogen-activated protein kinase 4 protein. These mice reportedly lack fetal liver hepatoblasts (Nishina et al., 1997a, 1997b, 1999; Watanabe et al., 2002). Morphological examination indicated that *Map2k4*^{-/-} mutant embryos developed normally except for their liver, which exhibited an unusual pouch-like morphology and contained hematopoietic cells. The hematopoietic activity of these cells is reportedly normal (Nishina et al., 1999). Although it is formally possible that MAPK signaling could directly impact ECM factor expression, our findings overall strongly suggest that down-regulation of Fibronectin and Vitronectin production is due to loss of hepatoblasts.

We also show that TGF-beta-1/TGFR-2 signaling functions in ECM production by fetal liver cells, predominantly hepatoblasts. TGF-beta-1/TGFR-2 signaling regulates diverse processes such as cell growth, differentiation, and apoptosis in adult animals and in embryogenesis (Shi and Massague, 2003; Watabe et al., 2003; Moustakas and Heldin, 2009). We found that sinusoid endothelial cells, hematopoietic cells and hepatoblasts express TGF-beta-1 mRNA and protein. Flow cytometry analysis showed that TGFR-2 was expressed in 1.8% of hematopoietic cells, 56.2% of hepatoblasts and

99% of sinusoid endothelial cells, suggesting that hepatoblasts and sinusoid endothelial cells are affected by TGF-beta-1/TGFR-2 signaling to a greater extent than hematopoietic cells. The observation that a high proportion of sinusoid endothelial cells expresses TGFR-2 is compatible with previous reports that TGF-beta-1/TGFR-2 signaling controls sinusoid endothelial cell differentiation in addition to normal angiogenesis (Shi and Massague, 2003; Watabe et al., 2003; Moustakas and Heldin, 2009; Yoshida et al., 2007). Interestingly, half of all hepatoblasts expressed TGFR-2, suggesting a functional separation of hepatoblasts based on TGFR-2 expression. Although expression levels of *Tgfb2* and *Tgfb3* are lower than that of *Tgfb1* in fetal liver at both 12.5 and 14.5 dpc (Fig. 4A), we cannot exclude the possibility that these factors function in ECM production by hepatoblasts, since *Tgfb1*-deficient mouse embryos exhibit no gross embryonic abnormalities, suggesting a compensatory mechanism (Shull et al., 1992).

Taken together with data showing that TGF-beta-1 up-regulates *Vtn*, *Fn1* and *Tnc* expression *in vitro*, TGF-beta-1/TGFR-2 signaling likely regulates ECM-production in fetal liver hepatoblasts *in vivo*, facilitating interactions with Integrins. In embryos injected with either TGF-beta receptor type-1 Kinase Inhibitor or TGF-beta receptor type-1 Kinase Inhibitor II, the number of fetal liver cells was significantly decreased after 12 h of whole embryo culture (Fig. S5). It is also possible that treatment with TGF-beta-1 inhibitors may alter cell proliferation. That possibility will be investigated in future studies.

Financial support

The authors acknowledge grant support from the Special Coordination Funds for Promoting Science and Technology, a Grant-in-Aid for Young Scientists (B) from The Ministry of Education, Culture, Sports, Science and Technology, a Grant-in-Aid by Ministry of Health, Labor and Welfare, Bilateral Joint Projects for the Japan Society for the Promotion of Science, and the Tokyo Biochemical Research Foundation.

Author contributions

D. S. designed and performed the research, analyzed data and wrote the paper. K. K. and C. M. performed research.

Acknowledgements

We thank the Research Support Center, the Graduate School of Medical Sciences, Kyushu University and Olympus Corporation, for technical support, Drs. T. Suda, K. Akashi and K. Tani for helpful discussion, Dr. T. Inoue, Miss Y. Horio and Miss Tan for technical support, and Dr. Elise Lamar for critical reading of the manuscript.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.mod.2012.09.003>.

REFERENCES

- Arroyo, A.G., Yang, J.T., Rayburn, H., Hynes, R.O., 1999. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. *Immunity* 11, 555–566.
- Bader, B.L., Rayburn, H., Crowley, D., Hynes, R.O., 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. *Cell* 95, 507–519.
- Chimal-Monroy, J., Diaz de Leon, L., 1999. Expression of N-cadherin, N-CAM, fibronectin and tenascin is stimulated by TGF-beta1, beta2, beta3 and beta5 during the formation of precartilaginous condensations. *Int. J. Dev. Biol.* 43, 59–67.
- Cudennec, C.A., Thiery, J.P., Le Douarin, N.M., 1981. *In vitro* induction of adult erythropoiesis in early mouse yolk sac. *Proc. Natl. Acad. Sci. USA* 78, 2412–2416.
- Dzierzak, E., Medvinsky, A., de Bruijn, M., 1998. Qualitative and quantitative aspects of hematopoietic cell development in the mammalian embryo. *Immunol. Today* 19, 228–236.
- Ema, H., Nakauchi, H., 2000. Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. *Blood* 95, 2284–2288.
- Frisch, S.M., Ruoslahti, E., 1997. Integrins and anoikis. *Curr. Opin. Cell Biol.* 9, 701–706.
- Gaggioli, C., Deckert, M., Robert, G., Abbe, P., Batoz, M., Ehrengreber, M.U., Ortonne, J.P., Ballotti, R., Tartare-Deckert, S., 2005. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. *Oncogene* 24, 1423–1433.
- George, E.L., Georges-Labouesse, E.N., Patel-King, R.S., Rayburn, H., Hynes, R.O., 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. *Development* 119, 1079–1091.
- Hirsch, E., Iglesias, A., Potocnik, A.J., Hartmann, U., Fassler, R., 1996. Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta-1 integrins. *Nature* 380, 171–175.
- Houssaint, E., 1981. Differentiation of the mouse hepatic primordium. II. Extrinsic origin of the haemopoietic cell line. *Cell Differ.* 10, 243–252.
- Huang, X.Z., Wu, J.F., Ferrando, R., Lee, J.H., Wang, Y.L., Farese Jr., R.V., Sheppard, D., 2000. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. *Mol. Cell Biol.* 20, 5208–5215.
- Humphries, M.J., Obara, M., Olden, K., Yamada, K.M., 1989. Role of fibronectin in adhesion, migration, and metastasis. *Cancer Invest.* 7, 373–393.
- Hynes, R.O., Yamada, K.M., 1982. Fibronectins: multifunctional modular glycoproteins. *J. Cell Biol.* 95, 369–377.
- Inoue, T., Sugiyama, D., Kurita, R., Oikawa, T., Kulkeaw, K., Kawano, H., Miura, Y., Okada, M., Suehiro, Y., Takahashi, A., Marumoto, T., Inoue, H., Komatsu, N., Tani, K., 2011. APOA-1 is a novel marker of erythroid cell maturation from hematopoietic stem cells in mice and humans. *Stem Cell Rev.* 7, 43–52.
- Johnson, G.R., Jones, R.O., 1973. Differentiation of the mammalian hepatic primordium in vitro. I. Morphogenesis and the onset of haematopoiesis. *J. Embryol. Exp. Morphol.* 30, 83–96.
- Johnson, G.R., Moore, M.A., 1975. Role of stem cell migration in the initiation of mouse foetal liver haemopoiesis. *Nature* 258, 726–728.
- Klein, G., Beck, S., Müller, C.A., 1993. Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment. *J. Cell Biol.* 123, 1027–1035.
- Kulkeaw, K., Mizuuchi, C., Horio, Y., Osumi, N., Tsuji, K., Sugiyama, D., 2009. Application of whole embryo culture system on stem cell research. *Stem Cell Rev.* 5, 175–180.
- Laping, N.J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J.F., Olson, B.A., 2002. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. *Mol. Pharmacol.* 62, 58–64.
- Lodish, H., Flygare, J., Chou, S., 2010. From stem regulation of red cell production at multiple levels by multiple hormones. *Life* 62, 492–496.
- Long, M.W., Dixit, V.M., 1990. Thrombospondin functions as a cytoadhesion molecule for human hematopoietic progenitor cells. *Blood* 75, 2311–2318.
- Long, M.W., Briddell, R., Walter, A.W., Bruno, E., Hoffman, R., 1992. Human hematopoietic stem cell adherence to cytokines and matrix molecules. *J. Clin. Invest.* 90, 251–255.
- Moustakas, A., Heldin, C.H., 2009. The regulation of TGF- β signal transduction. *Development* 136, 3699–3714.
- Mouta Carreira, C., Nasser, S.M., di Tomaso, E., Padera, T.P., Boucher, Y., Tomarev, S.I., Jain, R.K., 2001. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. *Cancer Res.* 61, 8079–8084.
- Nakamura, T., Miller, D., Ruoslahti, E., Border, W.A., 1992. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. *Kidney Int.* 41, 1213–1221.
- Nishina, H., Bachmann, M., Oliveira-dos-Santos, A.J., Kozieradzki, I., Fischer, K.D., Odermatt, B., Wakeham, A., Shahinian, A., Takimoto, H., Bernstein, A., Mak, T.W., Woodgett, J.R., Ohashi, P.S., Penninger, J.M., 1997a. Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. *J. Exp. Med.* 186, 941–953.
- Nishina, H., Fischer, K.D., Radvanyi, L., Shahinian, A., Hakem, R., Rubie, E.A., Bernstein, A., Mak, T.W., Woodgett, J.R., Penninger, J.M., 1997b. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. *Nature* 385, 350–353.
- Nishina, H., Vaz, C., Billia, P., Nghiem, M., Sasaki, T., De la Pompa, J.L., Furlonger, K., Paige, C., Hui, C., Fischer, K.D., Kishimoto, H., Iwatsubo, T., Katada, T., Woodgett, J.R., Penninger, J.M., 1999. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. *Development* 126, 505–516.
- Osumi-Yamashita, N., Ninomiya, Y., Eto, K., 1997. Mammalian craniofacial embryology in vitro. *Int. J. Dev. Biol.* 41, 187–194.
- Patel, V.P., Lodish, H.F., 1987. A fibronectin matrix is required for differentiation of murine erythroleukemia cells into reticulocytes. *J. Cell Biol.* 105, 3105–3118.
- Sasaki, K., Sonoda, Y., 2000. Histometrical and three-dimensional analyses of liver hematopoiesis in the mouse embryo. *Arch. Histol. Cytol.* 63, 137–146.
- Sasaki, T., Mizuuchi, C., Horio, Y., Nakao, K., Akashi, K., Sugiyama, D., 2010. Regulation of hematopoietic cell clusters in the placental niche through SCF/Kit signaling in embryonic mouse. *Development* 137, 3941–3952.
- Shi, Y., Massague, J., 2003. Mechanisms of TGF-signaling from cell membrane to the nucleus. *Cell* 113, 685–700.
- Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., Annunziata, N., Doetschman, T., 1992. Targeted disruption of the mouse transforming growth factor- β 1 gene results in multifocal inflammatory disease. *Nature* 359, 693–699.
- Strobel, E.S., Möbest, D., von Kleist, S., Dangel, M., Ries, S., Mertelsmann, R., Henschler, R., 1997. Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. *Blood* 90, 3524–3532.

- Sugiyama, D., Tsuji, K., 2006. Definitive hematopoiesis from endothelial cells in the mouse embryo; a simple guide. *Trends Cardiovasc. Med.* 16, 45–49.
- Sugiyama, D., Arai, K., Tsuji, K., 2005. Definitive hematopoiesis from acetyl LDL incorporating endothelial cells in the mouse embryo. *Stem Cells Dev.* 14, 687–696.
- Sugiyama, D., Kulkeaw, K., Mizuochi, C., Horio, Y., Okayama, S., 2011. Hepatoblasts comprise a niche for fetal liver erythropoiesis through cytokine production. *Biochem. Biophys. Res. Commun.* 410, 301–306.
- Sugiyama, D., Ogawa, M., Hirose, I., Jaffredo, T., Arai, K., Tsuji, K., 2003. Erythropoiesis from acetyl LDL incorporating endothelial cells at the pre-liver stage. *Blood* 101, 4733–4738.
- Suzuki, N., Suwabe, N., Ohneda, O., Obara, N., Imagawa, S., Pan, X., Motohashi, H., Yamamoto, M., 2003. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. *Blood* 102, 3575–3583.
- Taipale, J., Keski-Oja, J., 1997. Growth factors in the extracellular matrix. *FASEB J.* 11, 51–59.
- Tanimizu, N., Nishikawa, M., Saito, H., Tsujimura, T., Miyajima, A., 2003. Isolation of hepatoblasts based on the expression of Dlk/Pref-1. *J. Cell Sci.* 116, 1775–1786.
- Taverna, D., Disatnik, M.H., Rayburn, H., Bronson, R.T., Yang, J., Rando, T.A., Hynes, R.O., 1998. Dystrophic muscle in mice chimeric for expression of alpha5 integrin. *J. Cell Biol.* 143, 849–859.
- Tsai, S., Patel, V., Beaumont, E., Lodish, H.F., Nathan, D.G., Sieff, C.A., 1987. Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin. *Blood* 69, 1587–1594.
- Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., Nishikawa, S., Miyazono, K., 2003. TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. *J. Cell Biol.* 163, 1303–1311.
- Watanabe, T., Nakagawa, K., Ohata, S., Kitagawa, D., Nishitai, G., Seo, J., Tanemura, S., Shimizu, N., Kishimoto, H., Wada, T., Aoki, J., Arai, H., Iwatsubo, T., Mochita, M., Watanabe, T., Satake, M., Ito, Y., Matsuyama, T., Mak, T.W., Penninger, J.M., Nishina, H., Katada, T., 2002. SEK1/MKK4-Mediated SAPK/JNK signaling participates in embryonic hepatoblast proliferation via a pathway different from NF-B-induced anti-apoptosis. *Dev. Biol.* 250, 332–347.
- Williams, D.A., Rios, M., Stephens, C., Patel, P.V., 1991. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. *Nature* 352, 438–441.
- Yanai, N., Sekine, C., Yagita, H., Obinata, M., 1994. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. *Blood* 83, 2844–2850.
- Yoshida, M., Nishikawa, Y., Omori, Y., Yoshioka, T., Tokairin, T., McCourt, P., Enomoto, K., 2007. Involvement of signaling of VEGF and TGF-beta in differentiation of sinusoidal endothelial cells during culture of fetal rat liver cells. *Cell Tissue Res.* 329, 273–282.
- Zheng, X., Saunders, T.L., Camper, S.A., Samuelson, L.C., Ginsburg, D., 1995. Vitronectin is not essential for normal mammalian development and fertility. *Proc. Natl. Acad. Sci. USA* 92, 12426–12430.
- Ziyadeh, F.N., Sharma, K., Ericksen, M., Wolf, G., 1994. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. *J. Clin. Invest.* 93, 536–542.

REVIEW

Zebrafish erythropoiesis and the utility of fish as models of anemia

Kasem Kulkeaw and Daisuke Sugiyama* **{AU Query: are the following author initials correct for inclusion in the PubMed Database: 'Kulkeaw K, Sugiyama D'?**}

Abstract

Erythrocytes contain oxygen-carrying hemoglobin to all body cells. Impairments in the generation of erythrocytes, a process known as erythropoiesis, or in hemoglobin synthesis alter cell function because of decreased oxygen supply and lead to anemic diseases. Thus, understanding how erythropoiesis is regulated during embryogenesis and adulthood is important to develop novel therapies for anemia. The zebrafish, *Danio rerio*, provides a powerful model for such study. Their small size and the ability to generate a large number of embryos enable large-scale analysis, and their transparency facilitates the visualization of erythroid cell migration. Importantly, the high conservation of hematopoietic genes among vertebrates and the ability to successfully transplant hematopoietic cells into fish have enabled the establishment of models of human anemic diseases in fish. In this review, we summarize the current progress in our understanding of erythropoiesis on the basis of zebrafish studies and highlight fish models of human anemias. These analyses could enable the discovery of novel drugs as future therapies.


Introduction

Red blood cells, or erythrocytes, carry hemoglobin to supply oxygen to all tissues and organs. Approximately 2×10^{13} erythrocytes circulate throughout the whole body. In humans, more than 10^{11} new erythrocytes are generated daily from bone marrow (BM) through a process known as erythropoiesis [1]. In the BM, the hierarchy of erythropoiesis is topped by hematopoietic

stem cells (HSCs), which first differentiate into common myeloid and common lymphoid progenitors. Common lymphoid and myeloid progenitors give rise to the adaptive and innate immune systems, respectively. Common myeloid progenitors differentiate into megakaryocyte/erythroid progenitors and granulocyte/monocyte progenitors. At the same time, common lymphoid progenitors differentiate into B lymphocytes, T lymphocytes, and natural killer cells. Megakaryocyte/erythroid progenitors later give rise to erythrocytes or thrombocytes (platelets), whereas granulocyte/monocyte progenitors give rise to granulocytes (neutrophils, eosinophils, and basophils), monocytes, and dendritic cells (Figure 1). Erythrocytes synthesize hemoglobin, which is composed of two β -globin subunits and two α -globin subunits that interact with an iron-containing heme moiety. Intrinsic transcription factors and extrinsic signaling molecules coordinately regulate erythroid differentiation and hemoglobin synthesis. Impaired erythrocyte production or hemoglobin synthesis results in anemia and decreases the oxygen supply throughout the body, a condition known as hypoxia. Much of what we know about human erythropoiesis and anemic diseases comes from studies using animal models such as *Xenopus*, zebrafish, chicks, and mice [2-5].

Zebrafish (*Danio rerio*) is a teleost freshwater fish widely distributed throughout tropical and subtropical areas of South Asia, including India, Nepal, Bangladesh, and Northern Burma [6]. Zebrafish are known worldwide as models for the study of development, cell biology, physiology, and genetics. *In vivo* analyses using zebrafish have some advantages over those using **{AU Query: OK?}** mice. First and foremost, zebrafish produce large numbers of small-sized embryos, permitting drug screening and functional analysis of specific genes on a large scale. Second, zebrafish have a short life span (42 to 66 months) [7] and develop rapidly, requiring 90 days to develop into adults [7], shortening periods required for experiments. Third, zebrafish embryos are transparent and develop outside a uterus, enabling researchers to view zebrafish development and genetically manipulate embryos under a microscope. Finally, many zebrafish

*Correspondence: ds-mons@yb3.so-net.ne.jp
Division of Hematopoietic Stem Cells, Advanced Medical Initiatives, Department of Advanced, Medical Initiatives, Faculty of Medical Sciences, Kyushu University, Station for Collaborative Research 1, 4F, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582 Japan



gene functions are conserved in mice and humans, enabling researchers to translate results obtained in zebrafish studies to mammalian contexts. Currently, through large-scale mutagenesis, several models of human anemic diseases have been established in zebrafish, enabling us to develop novel therapies in anemias.

1. Development of zebrafish erythropoiesis


Like the generation of other blood cell types, zebrafish erythropoiesis takes place in the mesodermal germ layer and is classified into two sequential waves: primitive and definitive. The primitive wave generates erythrocytes and macrophages during embryonic development, whereas the definitive wave produces definitive HSCs, which can differentiate into every blood cell type (namely, erythrocytes, granulocytes, lymphocytes, and platelets), and maintains homeostasis throughout the zebrafish lifetime (Figure 2). To understand how erythropoiesis develops embryonically and is maintained in the adult, we also discuss the origin of erythrocytes from HSCs.

1.1. Primitive erythropoiesis

The fertilized egg, or zygote, **{AU Query: OK?}** divides and forms three germ layers: ectoderm, mesoderm, and endoderm; this process is known as gastrulation. Mesoderm gives rise to muscle, notochord, hematopoietic cells, pronephros, and blood vessels. Mesoderm is divided into dorsal and ventral mesoderm. Dorsal mesoderm develops into the notochord, whereas ventral mesoderm gives rise to hematopoietic cells, the pronephros, and blood vessels. Primitive hematopoiesis

intraembryonically starts in ventral mesoderm-derived tissue, known as the intermediate cell mass (ICM) (Figures 2 and 3). The ICM is located between the somites and yolk sac and consists of anterior and posterior ICM (Figure 3). At the two-somite stage, which is equivalent to 10 to 11 hours post fertilization (hpf), genes encoding transcription factors required for hematopoietic cell specification, such as T-cell acute lymphocytic leukemia 1 (*tal1*), GATA-binding protein 2a (*gata2a*), **{AU Query: per journal style, abbreviations of gene names should be in italics; please confirm whether this rule is applied correctly throughout the text}** and LIM domain only 2 (*lmo2*), and vasculogenesis, such as ets variant gene 2 (*etv2*), are co-expressed in both the anterior and posterior ICM, implying the existence of a common ancestor of hematopoietic and endothelial cells, known as the hemangioblast [8-10] (Figure 4). These genes are highly conserved among vertebrates [10-13]. Among proteins encoded by these genes, *tal1*, previously known as stem cell leukemia (*scl*), is a basic helix-loop-helix transcription factor required for both primitive and definitive hematopoiesis as well as endothelial cell differentiation, whereas *gata2a* is a zinc finger transcription factor functioning in proliferation and maintenance of hematopoietic progenitor cells (HPCs). Zebrafish *lmo2* is an LIM domain transcription factor that interacts with *tal1* and *gata2a*, forming a DNA-binding complex, which activates the transcription of both hematopoietic and endothelial genes [10]. Zebrafish *etv2*, previously known as ets1-related protein (*etsrp*), is an E-twenty six (*ets*) domain-containing factor that activates transcription of endothelial-specific genes essential for vasculogenesis [11]. The posterior ICM expresses GATA-binding protein 1a (*gata1a*), which encodes an erythroid-specific transcription factor, and spleen focus-forming virus (*SFFV*) proviral integration oncogene *spi1* (*spi1*), which encodes a myeloid-specific transcription factor, whereas the anterior ICM expresses only *spi1* [12,13]. These studies suggest that the ICM has been committed to erythroid and myeloid lineage. Between 12 and 24 hpf, the anterior ICM develops into myeloid cells (macrophages), whereas the posterior ICM develops primarily into erythroid and some myeloid cells (Figure 3).

At 20 to 24 hpf, primitive erythroid cells (proerythroblasts and erythroblasts) expressing *gata1a* are present in the posterior ICM [14] (Figure 2). Similar to the mammalian yolk sac, primitive erythroid cells are surrounded by endothelial cells [15]. After the onset of blood circulation at 24 hpf, *gata1a*⁺ primitive erythroid cells migrate throughout the embryo and differentiate into mature erythrocytes expressing aminolevulinate, delta-, synthetase 2 (*alas2*), which is an enzyme required for heme synthesis, and embryonic globin genes [16]. Unlike



similar cells in humans and mice, zebrafish erythrocytes are nucleated and oval in shape (Figure 4). Primitive erythropoiesis accounts for all circulating erythrocytes for the first 4 days after fertilization [15].


In zebrafish, primitive erythropoiesis is regulated intrinsically by transcription factors expressed in erythroid cells and extrinsically by erythropoietin secreted from surrounding cells and tissues. Zebrafish *gata1a*, a zinc finger transcription factor, activates the expression of erythroid-specific genes functioning in hemoglobin synthesis, iron utilization, and cell membrane stabilization. *Gata1a* also suppresses the expression of myeloid-specific genes [14]. As in the mouse, a nonsense mutation in the gene encoding zebrafish *gata1a* results in a lack of circulating erythrocytes at 26 hpf [17], suggesting a conservation of *gata1a* function among vertebrates. Unlike in the mouse, zebrafish primitive erythropoiesis depends on the extrinsic factor erythropoietin (*epo*). *Epo*

and *epo* receptor mRNA is detected in the ICM during 16 to 24 hpf. Knockdown of *epo receptor* impairs primitive erythropoiesis in fish [18].

1.2. Definitive erythropoiesis

In mice, definitive HSCs are defined as having the ability to reconstitute all blood cell types in lethally irradiated adult mice. Definitive HSCs are first detected in the aorta-gonad-mesonephros (AGM) region [19] and umbilical vessels [20] at mouse embryonic day 10 or 11. Definitive HSCs enter the blood circulation and colonize fetal liver, the first site of definitive hematopoiesis, where they expand and differentiate into erythroid and myeloid cells.

In zebrafish, an AGM-like region exists along the trunk in the space between the dorsal aorta and the underlying axial vein [21-24] (Figure 3). Cell-tracking and time-lapse imaging analyses indicate that HSCs and HPCs originate




directly from the ventral wall of dorsal aorta (VDA) at 26 hpf (Figure 2) [24,25]. The morphology of endothelial cells lining the VDA changes from a long flat shape to a round shape, and the cells egress into the subaortic space and enter the blood circulation via the axial vein (Figure 3), a process called endothelial-to-hematopoietic transition [24]. **{AU Query: edit of previous two sentences OK?}** As in mammals, runt-related transcription factor 1 (*runx1*) is critical for the emergence of hematopoietic cells from endothelial cells [26]. At 24 hpf, *runx1*-expressing HSCs and HPCs are observed in the VDA [27]. Later, at 26 hpf, dorsal aorta-derived *runx1*⁺ HSCs and HPCs start to express the transcription factor *cmyb* [28], which is required for HSC migration and differentiation but not for the endothelial-to-hematopoietic **{AU Query: OK?}** transition in zebrafish [29]. Later, *cmyb*⁺ HSCs and HPCs express integrin alpha 2b (*itga2b*), also known as *CD41* [30]. As in the mouse,

CD41 is the earliest HSC and HPC surface marker seen in endothelial cells lining on **{AU Query: is 'endothelial cell lining on' or 'endothelial cells lining' meant instead of 'endothelial cells lining on'??}** the dorsal aorta. Dorsal aorta-derived *CD41*⁺ HSCs and HPCs enter the blood circulation via the axial vein rather than the dorsal aorta and colonize caudal hematopoietic tissue by 48 hpf (Figure 3) [30]. This tissue, also known as the caudal vein plexus, is highly vascularized. From 48 hpf to 7 days post-fertilization (dpf), *cmyb*⁺ HSCs and HPCs expand and differentiate into erythrocytes, monocyte/macrophages, and thrombocytes in caudal hematopoietic tissue (Figures 2 and 3). Therefore, caudal hematopoietic tissue exhibits properties similar to those of the **{AU Query: OK?}** mammalian fetal liver. Next, HSCs and HPCs migrate from the caudal hematopoietic tissue first to the thymus and then to the pronephros [21-23] (Figure 2). *CD41*⁺ HSCs and HPCs first appear in the thymus at 54 hpf (2.25 dpf) [23], and by 4 dpf, *cmyb*⁺ HSCs and HPCs appear in the pronephros (Figure 2), which later develops into the kidney and functions equivalently to mammalian BM [21,22]. Two routes of HSC migration from the AGM-like region to the pronephros have been proposed: the first to caudal hematopoietic tissue and pronephros via the circulation (Figure 3) and the second directly from the AGM-like region via the pronephric tubules [30]. At 4 dpf, only myeloerythroid lineages have progressively expanded in the kidney [15]. By 7 dpf, erythroblasts are found in the kidney [15], where they later become the major definitive hematopoietic organ of adult zebrafish.

2. Erythropoiesis in adult zebrafish

In mammals, adult erythropoiesis is maintained primarily in the BM. HSCs differentiate into erythroid progenitor cells and later erythroblasts. Subsequently, erythroblasts undergo terminal differentiation into mature erythrocytes. Mature erythrocytes are spherical and biconcave with a typical size of 7 to 8 μm . As in embryos, cell-extrinsic cues, such as erythropoietin, and cell-intrinsic cues, such as erythroid-specific transcription factors *Gata1* and *Kruppel-like factor 1* (*Klf1*), coordinately regulate erythropoiesis in the BM [31].

Unlike in mammals, zebrafish erythropoiesis is maintained in the interstitium of the anterior and posterior kidney [2]. In adult kidney marrow, common myeloid progenitors differentiate into megakaryocyte/erythroid progenitors expressing the transcription factor *gata1a*, an ortholog of mouse *Gata1*. The megakaryocyte/erythroid progenitors differentiate into erythroblasts. Erythroblasts later differentiate into mature erythrocytes, which are elliptical and nucleated cells with a typical size of 7 \times 10 μm [32].



Although kidney marrow erythrocytes can be fractionated from blood cell mixtures by flow cytometry based on forward and side scatter (which reveal cell size and granularity, respectively), their surface markers have not been fully identified [33]. Although some potentially useful antibodies cross-react among species, it remains a challenge to analyze erythroid cells by using antibody-based techniques, owing to a shortage of reagents.

As in mammals, zebrafish erythrocytes contain hemoglobin. Human and mouse α -globin and β -globin genes are located on separate chromosomes and arranged in order of embryonic and adult expression. The change from embryonic to adult globin expression is known as globin switching [34]. By contrast, zebrafish α -globin and β -globin genes are located on the same chromosome and found in embryonic and adult clusters separated by non-coding genomic DNA [35]. The embryonic cluster consists of hemoglobin alpha embryonic-1 (*hbae1*) and hemoglobin beta embryonic-1.1 (*hbbe1.1*), whereas the adult cluster contains hemoglobin alpha adult-1 (*hbaa1*) and beta adult-1 globin (*ba1*). Moreover, in the adult

cluster, globin genes are oriented in a head-to-head pattern: 3'-5' in the case of α -globin and 5'-3' in the case of β -globin genes. Thus, they are transcribed in the opposite direction [36]. High-performance liquid chromatography analysis shows that adult zebrafish erythrocytes in peripheral blood contain three major α -globin and two β -globin proteins [36]. As in mammals, globin switching also occurs during zebrafish development at a stage 10 dpf **{AU Query: OK?}** [36]. As in embryos, adult zebrafish erythropoiesis is regulated by extrinsic and intrinsic cues.

2.1. Zebrafish erythropoietin

Erythropoietin (Epo) is a glycoprotein crucial for survival and proliferation of erythroid progenitor cells. In mammals, there is only one Epo gene and its protein **{AU Query: insert 'is' here?}** primarily produced from kidney and BM [37]. Binding of EPO to its receptor activates Janus kinase/signal transducer and activator of transcription 5 (JAK/STAT5) signaling pathway, which upregulates anti-apoptotic genes and promotes cell survival [31].

Mammalian EPO is not required for primitive erythropoiesis but is indispensable for definitive erythropoiesis [38,39].

Unlike the case in mice, erythropoiesis of both primitive and definitive zebrafish depends on erythropoietin signaling [18]. Unlike the case with the mammalian *Epo* gene, there are three splice variants of *epo* gene in fish: *epo-L1*, *epo-L2*, and *epo-S* [40]. *epo-L1* and *epo-L2* are expressed predominantly in the heart and liver, whereas *epo-S* is expressed in adult kidney marrow [40,41]. The C-terminal amino acid sequences of proteins encoded by these genes are identical, but the N-terminal signal peptides differ. Misexpression studies in the monkey kidney fibroblast COS-1 cell line indicate that *epo-L1* and *epo-L2* are secreted but that *epo-S* is cytosolic [40].

In mammals, decreased blood oxygen because of anemia or hypoxia induces EPO production in the kidney and accelerates erythropoiesis. Similarly, anemia and hypoxia upregulate the expression of zebrafish *epo* mRNA in the heart [18]. Moreover, zebrafish erythropoietin signaling requires *stat5.1* protein, an ortholog of human *STAT5* [18]. These observations demonstrate that *epo/epor* function is highly conserved among vertebrates.

2.2. Zebrafish erythroid transcription factors

In the mouse, *Gata1* regulates transcription of erythropoietic genes, including *Klf1*. *Gata1* knockout mice die during gestation because of severe anemia [42]. Like *Gata1*, mouse *Klf1* is essential for definitive erythropoiesis in fetal liver [43]. *Klf1* reportedly regulates the expression of several erythroid-specific genes encoding (a) globin, (b) enzymes for heme biosynthesis, and (c) erythroid membrane and cytoskeletal proteins [44].

Little is known about the role of *gata1a* in adult erythropoiesis because of the lethal phenotype of null mutants at an early stage of development [17]. In addition, no functional ortholog of mouse *Klf1* has been identified in zebrafish. Although the zebrafish *klfd* gene is expressed in both primitive and definitive erythropoietic organs [45] and the amino acid sequence of zebrafish *klfd* is similar to that of mouse *Klf1* [45], there is currently no direct evidence that *klfd* functions in definitive erythropoiesis. Zebrafish *klfd* knockdown using antisense morpholino oligonucleotides downregulates the expression of embryonic β -globin and genes involved in heme biosynthesis, but no defect is seen in definitive erythropoiesis [46]. Therefore, it is unlikely that *klfd* is the ortholog of mouse *Klf1*. Thus, owing to the lack of a model, the roles of *gata1a* and *klfd* in adult erythropoiesis have not been clarified. These outcomes prompted us to establish transient and reversible downregulation of both transcription factors in adult zebrafish, as discussed in section 3.8.

3. Zebrafish as models of human erythropoiesis-related diseases

Zebrafish erythropoietic genes are functionally similar to those expressed in mice and humans and include genes encoding enzymes for heme biosynthesis, structural erythrocyte membrane proteins, *epo/epo* receptor, and globin [47]. Large-scale mutagenesis of zebrafish has enabled the identification of genes regulating hematopoiesis/erythropoiesis [32,48]. The human homologs of some of these genes function in hematological diseases [3]. Zebrafish are advantageous for evaluating the function of genes underlying erythropoietic disease since fish embryos are resistant to severe anemic conditions because of passive diffusion of oxygen into the fish. Fish models of human anemias (Table 1) are described below. Many of the following mutants could be useful to test new drugs.

3.1. Erythropoietic protoporphyria

Erythropoietic protoporphyria occurs worldwide, has a prevalence of 1:75,000 in The Netherlands [49], and is caused by ferrochelatase deficiency. Ferrochelatase catalyzes the formation of heme by transferring iron to protoporphyrin, a heme intermediate. Mutations in the human ferrochelatase gene promote protoporphyrin accumulation in the skin, erythrocytes, and liver, resulting in sensitivity to light exposed to {AU Query: OK?} the skin or even erythrocytes and skin burning and itching [49]. Among patients, 20% to 60% also exhibit anemia due to decreased heme synthesis and light-dependent erythrocyte lysis. Some patients (1% to 4%) show liver disease due to the accumulation of free protoporphyrin released from lysed erythrocytes [49]. Although the avoidance of sun exposure and treatment with light-protective substances such as β -carotene and melanin in skin can ameliorate symptoms, no curative treatment is yet available [49].

The zebrafish mutant *dracula* exhibits a point mutation in the ferrochelatase gene, creating an in-frame stop codon and expression of a dysfunctional enzyme. *Dracula* fish manifest autofluorescent erythrocytes, light-dependent hemolysis, and liver malfunction, similar to conditions seen in humans [50]. Owing to the transparency of fish embryos and protoporphyrin autofluorescence, protoporphyrin accumulation can be monitored microscopically in various organs of an intact fish, an analysis impossible in humans and mice, making *dracula* mutants a suitable model for human erythropoietic protoporphyria.

3.2. Hemolytic anemia

Abnormality of erythroid cell membrane leads to massive erythrocyte destruction in the spleen, a condition {AU Query: OK?} known as hemolytic anemia. Human hereditary elliptocytosis is characterized by elliptical

Table 1. Zebrafish mutant strains relevant to human erythropoiesis-related diseases

Human disease	Mutant	Gene	Function	Reference
Erythropoietic protoporphyria	<i>dracula</i>	Ferrochelatase	Enzyme functioning in heme synthesis	[50]
Hemolytic anemia	<i>merlot</i>	Erythrocyte membrane protein 4.1R	Structural protein of erythrocyte membrane Stabilizes β -spectrin/actin interaction	[54]
Congenital dyserythropoietic anemia type II (HEMPAS)	<i>retsina</i>	Solute carrier family 4 (anion exchanger 1a or band 3)	Chloride exchanger	[56]
Hereditary spherocytosis	<i>riesling</i>	β -spectrin	Structural protein of erythrocyte membrane	[59]
Congenital sideroblastic anemia	<i>sauternes</i>	Aminolevulinatase synthetase 2 (alas2)	Enzyme functioning in heme synthesis	[63]
Hypochromic anemia (resembles thalassemia)	<i>zinfandel</i>	Globin	Oxygen transport	[35]
Type IV hemochromatosis	<i>weissherbst</i>	Ferroportin 1	Iron transport	[65]

HEMPAS, **{AU Query: please expand}**. **{AU Query: edit of Table 1 OK?}**

erythrocytes, in which abnormal cell membranes lead to hemolytic anemia. Human hereditary elliptocytosis occurs worldwide but is prevalent in West Africa [51]. Often patients show no symptoms, and only 10% have mild to severe anemia [51]. In human hereditary elliptocytosis, many patients harbor point mutations in the gene encoding protein 4.1R, a major component of the erythrocyte cytoskeleton that maintains biconcave morphology. These mutations promote decreased protein expression or impair protein interaction with other cytoskeletal proteins [52]. Owing to massive hemolysis, patients with hereditary elliptocytosis have complications such as cardiomegaly, splenomegaly, and gallstones. Only supportive treatments, such as folate therapy, blood transfusion, splenectomy, and gallstone removal, are currently available [51,53]. Although HSC transplantation is one curative therapy, novel drugs are needed to antagonize hemolysis.

The zebrafish *merlot* mutant exhibits severe hemolytic anemia due to mutation in the gene encoding 4.1R protein. Unlike mammalian erythrocytes, wild-type mature zebrafish erythrocytes exhibit both spherical and elliptical morphologies. *Merlot* mutants show spiculated erythrocyte membranes, resulting in hemolytic anemia and conditions such as cardiomegaly and splenomegaly, phenotypes similar to those seen in humans [54].

3.3. Congenital dyserythropoietic anemia type II

Human congenital dyserythropoietic anemia type II is an erythroid-specific abnormality in cell division, leading to multinuclear erythroblasts, erythroblast apoptosis (dyserythropoiesis), and anemia. The condition varies from mild to severe: approximately 15% of patients require blood transfusions during infancy and early childhood but not thereafter [55]. Splenomegaly occurs in 50% to 60% of patients, and gallstones are frequently observed. In the BM, 10% to 45% of erythroblasts are bi- and **{AU Query: is 'or' meant instead of 'and'?** multi-nucleated

[55]. Dyserythropoiesis is caused by a mutation in the anion exchanger protein band 3, which is present in the human erythrocyte membrane [55]. The zebrafish *retsina* mutant exhibits erythroid-specific defects in cell division because of mutation in the fish ortholog of the band 3 gene. These defects resemble those of **{AU Query: OK?}** the human disease [56]. Severely affected anemic patients require blood transfusion and HSC transplantation [57].

3.4. Hereditary spherocytosis

Human hereditary spherocytosis is a hemolytic anemia common in Caucasians and has a prevalence of 1:2,000 to 1:5,000 [53]. Hereditary spherocytosis is characterized by abnormal erythrocyte morphology. Normally, the shape of human erythrocytes is a biconcave disk. In hereditary spherocytosis, the erythrocytes exhibit a spherical shape, leading to their massive destruction in the spleen. Mutation in the gene encoding the cytoskeletal protein spectrin has been identified as a **{AU Query: is 'the' meant instead of 'a'?** cause of human hereditary spherocytosis. Erythroid spectrin stabilizes membrane bilayers [58]. Anemia ranging from mild (blood transfusion-independent) to severe (blood transfusion-dependent) is the main clinical feature of this condition. Patients also exhibit hyperbilirubinemia, causing jaundice, and splenomegaly. The zebrafish *riesling* carries a mutant β -spectrin gene and exhibits anemia due to erythrocyte hemolysis, similar to conditions seen in humans [59]. Zebrafish β -spectrin shares 62.3% identity with the human ortholog. In addition to **{AU Query: word missing here? ('undergoing' or 'exhibiting'?)}** abnormal cell morphology-induced hemolysis, zebrafish *riesling* erythrocytes undergo apoptosis, which had not been observed in human hereditary spherocytosis. Thus, analysis of the zebrafish *riesling* mutant has revealed a novel mechanism of erythrocyte hemolysis [59].

3.5. Congenital sideroblastic anemia

Human congenital sideroblastic anemia is characterized by iron deposition in mitochondria of erythroblasts in the BM and is caused by a mutation in the gene encoding δ -aminolevulinic synthase, or ALAS2, which catalyzes the first step of heme biosynthesis. A lack of heme promotes increases in free iron levels and subsequent iron deposition in erythroblast mitochondria, causing insufficient production of mature erythrocytes [60]. Generally, patients have symptoms of anemia, such as skin paleness, fatigue, dizziness, and enlargement of the spleen and liver. In addition to a decrease of mature erythrocytes, hypochromic microcytic erythrocytes are observed in the patients. Heme reportedly promotes gene expression of β -globin through binding Bcl11, a transcriptional repressor of β -globin gene [61,62]. Therefore, decreased intracellular heme because of mutated ALAS2 may contribute to hypochromic microcytic anemia. Mutation in the zebrafish gene *sauternes*, which encodes alas2 protein, results in a condition similar to hypochromic microcytic anemia in humans [63]. *Sauternes* mutant embryos show delayed erythrocyte maturation and decreased β -globin expression. These mutants represent the first animal model to allow the investigation of mechanisms underlying heme-induced globin synthesis.

3.6. Hypochromic anemia

Hypochromic anemia is a general term for anemia in which erythrocytes look paler and smaller than they do normally. In humans, hypochromic anemia results from reduction in either globin synthesis (as occurs in thalassemia) or iron absorption (as occurs in iron deficiency) or from vitamin B₆ deficiency. In mammals and fish, different globin subtypes are expressed in embryonic and adult stages. In adult mammals, embryonic globin synthesis is suppressed whereas adult globin synthesis is activated [34]. Thalassemic patients show reduced adult globin synthesis and re-activate fetal globin expression, which can ameliorate anemia severity. The zebrafish *zinfandel* mutant exhibits hypochromic microcytic anemia due to defective embryonic globin production. This condition is rescued in adult fish once adult globin is produced [35].

3.7. Type IV hemochromatosis (iron overload)

Type IV hemochromatosis, or iron overload, is characterized by increased intestinal iron absorption and progressive iron deposition in various tissues, resulting in hepatic cirrhosis, arthritis, cardiomyopathy, diabetes, hypopituitarism, and **{AU Query: is 'or' meant instead of 'and'}** hyperpigmentation [64]. Its primary cause is mutation in genes encoding membrane proteins functioning in iron transportation, such as


hemochromatosis protein, the transferrin receptor, and hemojuvelin. Analysis of zebrafish *weissherbst* mutants revealed mutations in a novel iron transporter, named ferroportin 1 [65]—mutations later identified in patients with type IV hemochromatosis [66,67].

3.8. Other anemias

As noted, most zebrafish mutant lines with defects in erythropoiesis were generated by mutagenesis by using ethylnitrosourea [32,48]. These pioneering studies provided useful animal models of anemia and identified numerous genes underlying human anemias. Nonetheless, such screens take time and are expensive, prompting us to establish a novel, simpler anemic model.

It is known that temperature regulates hematopoiesis [68]. High temperature increases the number of hematopoietic cells in the BM of rats and the nine-banded armadillo (*Dasypus novemcinctus*), whereas low temperature has opposite effects [68]. However, in nature, zebrafish survive in a wide range of temperatures, from 6°C in winter to 38°C in summer [6], making them useful to investigate the effect of temperature on hematopoiesis. Previously, we established a novel reversible anemic model by keeping zebrafish at 17°C (cold zebrafish) [41]. By comparison with fish kept at a higher temperature (26.5°C), 'cold' zebrafish appear paler starting at the first week of cold exposure (Figure 5a, right panel). The kidney marrow of cold zebrafish shows abnormally structured renal tubules and erythrocyte clusters (Figure 5b, right panel). We examined the expression of genes essential for HSC maintenance, erythropoiesis, and myelopoiesis by real-time polymerase chain reaction (PCR). Interestingly, only HSC-regulated genes (*runx1*, *cmyb*, *gata2a*, and *tal1*) (data not shown) and erythropoietic genes (*gata1a*, *klf1*, *epo*, *epor*, *hbaa1*, and *ba1*) (Figure 5c) were down-regulated the first week of exposure. These genes were expressed at generally lower levels by the second week, suggestive of anemia. However, expression of *colony-stimulating factor 1a*, which is required for macrophage differentiation, and of *colony-stimulating factor 3* (granulocyte), which is required for granulocyte differentiation, was unchanged [41]. These results suggest that cold exposure specifically suppresses erythropoiesis. Moreover, cold-induced anemia was reversed when fish were returned to 26.5°C conditions, implying that phenotypes are directly caused by temperature [41].

To further identify novel genes regulating erythropoiesis mediated by cold exposure, we assessed global changes in gene expression in the kidney marrow by DNA microarray (unpublished data). Although decreased temperature suppressed enzymatic activity and resulted in a global decrease in gene expression, we observed both increased and decreased gene expression in the kidney marrow of cold zebrafish, as confirmed by real-time PCR.



We are now undertaking loss-of-function analysis of candidate factors by using antisense morpholino oligonucleotides and small interference RNAs in fish, and we are conducting gain-of-function analysis in mouse and human cell lines.

4. Conclusions

Defects in erythropoiesis result in various anemic diseases. To gain an understanding of these diseases, it is necessary to determine how erythropoiesis is regulated in normal conditions as well as to establish *in vivo* models. We propose that, in addition to several anemic mutants, our cold zebrafish model is a useful tool to explore novel genes functioning in erythropoiesis. {AU Query: edit of previous sentence OK?} Given the advantages of zebrafish models, it is feasible to reach these objectives. Knowledge of the etiology and molecular mechanisms underlying these conditions will lead to the development of novel therapies.

This article is part of a thematic series on *Stem cell research in the Asia-Pacific* edited by Oscar Lee, Songtao Shi, Yufang Shi, and Ying Jin. Other articles in the series can be found online at <http://stemcellres.com/series/asiapacific>.

Abbreviations

AGM, aorta-gonad-mesonephros; *ba1*, globin β 1; BM, bone marrow; *cmyb*, transcription factor *cmyb*; dpf, days post-fertilization; *epo*, erythropoietin; *etv2*, ets variant gene 2; *gata1a*, GATA-binding protein 1a; *gata2a*, GATA-binding protein 2a; *hbaa1*, hemoglobin alpha adult-1; HPC, hematopoietic progenitor cell; hpf, hours post fertilization; HSC, hematopoietic stem cell; ICM, intermediate cell mass; *klf*, Kruppel-like factor; *lmo2*, LIM domain only 2; PCR, polymerase chain reaction; *runx1*, runt-related transcription factor 1; *spi1*, spleen focus-forming virus proviral integration oncogene *spi1*; *stat5.1*, signal transducer and the activator of transcription 5.1; *tal1*, T-cell acute lymphocytic leukemia; VDA, ventral wall of dorsal aorta. {AU Query: edit of this section OK? (per journal style, this section includes only those abbreviations that are used more than once in the main text)}

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

We thank E {AU Query: please provide first name} Lamar and Keai Sinn for editing the manuscript and acknowledge grant support from the Tokyo Biochemical Research Foundation; the Japan Society for the Promotion of Science; the Ministry of Education, Culture, Sports, Science, and Technology; and the Ministry of Health, Labor, and Welfare. KK is a recipient of a fellowship supported by the Tokyo Biochemical Research Foundation and a postdoctoral fellowship for foreign researchers by the Japan Society for the Promotion of Science. {AU Query: edit of previous paragraph OK?}

Published: X Month 2012

References

1. Sieff C, Williams D: **Hematopoiesis**. In *Blood: Principles and Practice of Hematology*. Edited by Handin R, Lux S, Stossel T. Philadelphia: Lippincott, 1995:171-224.
2. Ciau-Uitz A, Walmsley M, Patient R: **Distinct origins of adult and embryonic blood in *Xenopus***. *Cell* 2000, **102**:787-796.
3. Amatruda JF, Zon LI: **Dissecting hematopoiesis and disease using the zebrafish**. *Dev Biol* 1999, **216**:1-15.
4. Godin I, Cumano A: **Of birds and mice: hematopoietic stem cell development**. *Int J Dev Biol* 2005, **49**:251-257.
5. Orkin SH, Zon LI: **Hematopoiesis: an evolving paradigm for stem cell biology**. *Cell* 2008, **132**:631-644.
6. Spence R, Gerlach G, Lawrence, Smith C: **The behavior and ecology of the zebrafish, *Danio rerio***. *Biol Rev* 2008, **83**:13-34.
7. **The Zebrafish Model Organism Database** [http://zfin.org].
8. Stainier DY, Weinstein BM, Detrich HW 3rd, Zon LI, Fishman MC: **Cloche, an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages**. *Development* 1995, **121**:3141-3150.
9. Vogeli KM, Jin SW, Martin GR, Stainier DY: **A common progenitor for haematopoietic and endothelial lineages in the zebrafish gastrula**. *Nature* 2006, **443**:337-339.
10. Patterson LJ, Gering M, Eckfeldt CE, Green AR, Verfaillie CM, Ekker SC, Patient R: **The transcription factors *Scf* and *Lmo2* act together during development of the hemangioblast in zebrafish**. *Blood* 2007, **109**:2389-2398.
11. Gomez G, Lee JH, Veldman MB, Lu J, Xiao X, Lin S: **Identification of vascular and hematopoietic genes downstream of *etsrp* by deep sequencing in zebrafish**. *PLoS One* 2012, **7**:e31658.
12. Detrich HW 3rd, Kieran MW, Chan FY, Barone LM, Yee K, Rundstadler JA, Pratt S, Ransom D, Zon LI: **Intraembryonic hematopoietic cell migration during vertebrate development**. *Proc Natl Acad Sci U S A* 1995, **92**:10713-10717.
13. Lieschke GJ, Oates AC, Paw BH, Thompson MA, Hall NE, Ward AC, Ho RK, Zon LI, Layton JE: **Zebrafish *SPI-1* (*PU.1*) marks a site of myeloid development independent of primitive erythropoiesis: implications for axial patterning**. *Dev Biol* 2002, **246**:274-295.
14. Galloway JL, Wingert RA, Thisse C, Thisse B, Zon LI: **Loss of *gata1* but not *gata2* converts erythropoiesis to myelopoiesis in zebrafish embryos**. *Dev Cell* 2005, **8**:109-116.
15. Willett CE, Cortes A, Zuasti A, Zapata AG: **Early hematopoiesis and developing lymphoid organs in the zebrafish**. *Dev Dyn* 1999, **214**:323-336.
16. Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S: **GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene**. *Development* 1997, **124**:4105-4111.
17. Lyons SE, Lawson ND, Lei L, Bennett PE, Weinstein BM, Liu PP: **A nonsense mutation in zebrafish *gata1* causes the bloodless phenotype in vlad tepes**. *Proc Natl Acad Sci U S A* 2002, **99**:5454-5459.
18. Paffett-Lugassy N, Hsia N, Fraenkel PG, Paw B, Leshinsky I, Barut B, Bahary N, Caro J, Handin R, Zon LI: **Functional conservation of erythropoietin signaling in zebrafish**. *Blood* 2007, **110**:2718-2726.
19. Mizuochi C, Fraser ST, Biasch K, Horio Y, Kikushige Y, Tani K, Akashi K, Tavian M, Sugiyama D: **Intra-aortic clusters undergo endothelial to hematopoietic phenotypic transition during early embryogenesis**. *PLoS One* 2012, **7**:e35763.
20. Sasaki T, Mizuochi C, Horio Y, Nakao K, Akashi K, Sugiyama D: **Regulation of hematopoietic cell clusters in the placental niche through *SCF/Kit* signaling in embryonic mouse**. *Development* 2010, **137**:3941-3952.
21. Murayama E, Kissa K, Zapata A, Mordelet E, Briolat V, Lin HF, Handin R, Herbomel P: **Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development**. *Immunity* 2006, **25**:963-975.
22. Jin H, Xu J, Wen Z: **Migratory path of definitive hematopoietic stem/progenitor cells during zebrafish development**. *Blood* 2007, **109**:5208-5214.
23. Kissa K, Murayama E, Zapata A, Cortés A, Perret E, Machu C, Herbomel P: **Live imaging of emerging hematopoietic stem cells and early thymus colonization**. *Blood* 2008, **111**:1147-1156.
24. Kissa K, Herbomel P: **Blood stem cells emerge from aortic endothelium by a novel type of cell transition**. *Nature* 2010, **464**:112-115.
25. Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D: **Haematopoietic stem cells derive directly from aortic endothelium during development**. *Nature* 2010, **464**:108-111.
26. Kaley-Zylinska ML, Horsfield JA, Flores MV, Postlethwait JH, Vitas MR, Baas AM, Crosier PS, Crosier KE: **Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis**. *Development* 2002, **129**:2015-2030.
27. Burns CE, DeBlasio T, Zhou Y, Zhang J, Zon L, Nimer SD: **Isolation and characterization of *runxa* and *runxb*, zebrafish members of the runt family of transcriptional regulators**. *Exp Hematol* 2002, **30**:1381-1389.
28. Gering M, Patient R: **Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos**. *Dev Cell* 2005, **8**:389-400.
29. Zhang Y, Jin H, Li L, Qin FX, Wen Z: **cMyb regulates hematopoietic stem/progenitor cell mobilization during zebrafish hematopoiesis**. *Blood* 2011, **118**:4093-4101.
30. Bertrand JY, Kim AD, Teng S, Traver D: **CD41+ cmyb+ precursors colonize the zebrafish pronephros by a novel migration route to initiate adult hematopoiesis**. *Development* 2008, **135**:1853-1862.
31. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF: **From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications**. *Blood* 2011, **118**:6258-6268.
32. Ransom DG, Haffter P, Odenthal J, Brownlie A, Vogelsang E, Kelsch RN, Brand M, van Eeden FJ, Furutani-Seiki M, Granato M, Hammerschmidt M, Heisenberg CP, Jiang YJ, Kane DA, Mullins MC, Nüsslein-Volhard C: **Characterization of zebrafish mutants with defects in embryonic hematopoiesis**. *Development* 1996, **123**:311-319.
33. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI: **Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants**. *Nat Immunol* 2003, **4**:1238-1246.
34. Wilber A, Nienhuis AW, Persons DA: **Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities**. *Blood* 2011, **117**:3945-3953.
35. Brownlie A, Hersey C, Oates AC, Paw BH, Falick AM, Witkowska HE, Flint J, Higgs D, Jessen J, Bahary N, Zhu H, Lin S, Zon L: **Characterization of embryonic globin genes of the zebrafish**. *Dev Biol* 2003, **255**:48-61.
36. Chan FY, Robinson J, Brownlie A, Shivdasani RA, Donovan A, Brugnara C, Kim J, Lau BC, Witkowska HE, Zon LI: **Characterization of adult alpha- and beta-globin genes in the zebrafish**. *Blood* 1997, **89**:688-700.
37. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z: **Cloning and expression of the human erythropoietin gene**. *Proc Natl Acad Sci U S A* 1985, **82**:7580-7584.
38. Lin CS, Lim SK, D'Agati V, Costantini F: **Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis**. *Genes Dev* 1996, **10**:154-164.
39. Lee R, Kertesz N, Joseph SB, Jegalian A, Wu H: **Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis**. *Blood* 2001, **98**:1408-1415.
40. Chu CY, Cheng CH, Yang CH, Huang CJ: **Erythropoietins from teleosts**. *Cell Mol Life Sci* 2008, **65**:3545-3552.
41. Kulkeaw K, Ishitani T, Kanemaru T, Fucharoen S, Sugiyama D: **Cold exposure down-regulates zebrafish hematopoiesis**. *Biochem Biophys Res Commun* 2010, **394**:859-864.
42. Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH: **Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor *GATA-1***. *Proc Natl Acad Sci U S A* 1996, **93**:12355-12358.
43. Perkins AC, Sharpe AH, Orkin SH: **Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor *EKLF***. *Nature* 1995, **375**:318-322.
44. Hodge D, Coghill E, Keys J, Maguire T, Hartmann B, McDowall A, Weiss M, Grimmond S, Perkins A: **A global role for *EKLF* in definitive and primitive erythropoiesis**. *Blood* 2006, **107**:3359-3370.
45. Oates AC, Pratt SJ, Vail B, Yan YI, Ho RK, Johnson SL, Postlethwait JH, Zon LI: **The zebrafish *kif* gene family**. *Blood* 2001, **98**:1792-1801.
46. Gardiner MR, Gongora MM, Grimmond SM, Perkins AC: **A global role for zebrafish *kif4* in embryonic erythropoiesis**. *Mech Dev* 2007, **124**:762-774.
47. Davidson AJ, Zon LI: **The 'definitive' (and 'primitive') guide to zebrafish hematopoiesis**. *Oncogene* 2004, **23**:7233-7246.
48. Weinstein BM, Schier AF, Abdelilah S, Malicki J, Solnica-Krezel L, Stemple DL, Stainier DY, Zwartkruis F, Driever W, Fishman MC: **Hematopoietic mutations in the zebrafish**. *Development* 1996, **123**:303-309.
49. Lecha M, Puy H, Deybach JC: **Erythropoietic protoporphyria**. *Orphanet J Rare Dis* 2009, **4**:19.
50. Childs S, Weinstein BM, Mohideen MA, Donohue S, Bonkovsky H, Fishman MC: **Zebrafish *dracula* encodes ferrochelatase and its mutation provides a model for erythropoietic protoporphyria**. *Curr Biol* 2000, **10**:1001-1004.
51. An X, Mohandas N: **Disorders of red cell membrane**. *Br J Haematol* 2008,

- 141:367-375.
52. Lorenzo F, Dalla Venezia N, Morlé L, Baklouti F, Alloisio N, Ducluzeau MT, Roda L, Lefrançois P, Delaunay J: **Protein 4.1 deficiency associated with an altered binding to the spectrin-actin complex of the red cell membrane skeleton.** *J Clin Invest* 1994, **94**:1651-1656.
53. Barcellini W, Bianchi P, Fermo E, Imperiali FG, Marcello AP, Vercellati C, Zaninoni A, Zanella A: **Hereditary red cell membrane defects: diagnostic and clinical aspects.** *Blood Transfus* 2011, **9**:274-277.
54. Shafizadeh E, Paw BH, Foott H, Liao EC, Barut BA, Cope JJ, Zon LI, Lin S: **Characterization of zebrafish merlot/chablis as non-mammalian vertebrate models for severe congenital anemia due to protein 4.1 deficiency.** *Development* 2002, **129**:4359-4370.
55. Denecke J, Marquardt T: **Congenital dyserythropoietic anemia type II (CD41/HEMPAS): where are we now?** *Biochim Biophys Acta* 2009, **1792**:915-920.
56. Paw BH, Davidson AJ, Zhou Y, Li R, Pratt SJ, Lee C, Tredre NS, Brownlie A, Donovan A, Liao EC, Ziai JM, Drejer AH, Guo W, Kim CH, Gwynn B, Peters LL, Chernova MN, Alper SL, Zapata A, Wickramasinghe SN, Lee MJ, Lux SE, Fritz A, Postlethwait JH, Zon LI: **Cell-specific mitotic defect and dyserythropoiesis associated with erythroid band 3 deficiency.** *Nat Genet* 2003, **34**:59-64.
57. Iolascon A, Sabato V, de Mattia D, Locatelli F: **Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II).** *Bone Marrow Transplant* 2001, **27**:213-215.
58. Viel A, Branton D: **Spectrin: on the path from structure to function.** *Curr Opin Cell Biol* 1996, **8**:49-55.
59. Liao EC, Paw BH, Peters LL, Zapata A, Pratt SJ, Do CP, Lieschke G, Zon LI: **Hereditary spherocytosis in zebrafish riesling illustrates evolution of erythroid beta-spectrin structure, and function in red cell morphogenesis and membrane stability.** *Development* 2000, **127**:5123-5132.
60. Cotter PD, Baumann M, Bishop DF: **Enzymatic defect in 'X-linked' sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinic synthase deficiency.** *Proc Natl Acad Sci U S A* 1992, **89**:4028-4032.
61. Fukuda Y, Fujita H, Garbaczewski L, Sassa S: **Regulation of β -globin mRNA accumulation by heme in DMSO-sensitive and DMSO-resistant murine erythroleukemia cells.** *Blood* 1994, **83**:1662-1667.
62. Igarashi K and Sun J: **The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation.** *Antioxid Redox Signal* 2006, **8**:107-118.
63. Brownlie A, Donovan A, Pratt SJ, Pratt SJ, Paw BH, Oates AC, Brugnara C, Witkowska HE, Sassa S, Zon LI: **Positional cloning of the zebrafish sauternes gene: a model for congenital sideroblastic anaemia.** *Nat Genet* 1998, **20**:244-250.
64. Franchini M: **Hereditary iron overload: update on pathophysiology, diagnosis, and treatment.** *Am J Hematol* 2006, **81**:202-209.
65. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI: **Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter.** *Nature* 2000, **403**:776-781.
66. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A: **Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.** *J Clin Invest* 2001, **108**:619-623.
67. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Moyo VM, Rouault TA, MacPhail P, Pietrangelo A: **Iron overload in Africans and African-Americans and a common mutation in the SLC40A1 (ferroportin 1) gene.** *Blood Cells Mol Dis* 2003, **31**:299-304.
68. Weiss LP, Wislocki GB: **Seasonal variations in hematopoiesis in the dermal bones of the nine-banded armadillo.** *Anat Rec* 1956, **126**:143-163.

doi:10.1186/scrtX

Cite this article as: Kulkeaw K, Sugiyama D: **Zebrafish erythropoiesis and the utility of fish as models of anemia.** *Stem Cell Research & Therapy* 2012, **3**:X.

Mesodermal and Hematopoietic Differentiation from ES and iPS Cells

Tomoko Inoue-Yokoo · Kenzaburo Tani ·
Daisuke Sugiyama

Published online: 9 June 2012
© Springer Science+Business Media, LLC 2012

Abstract Embryonic stem (ES) and induced pluripotent stem (iPS) cells can differentiate into any type of tissue when grown in a suitable culture environment and are considered valuable tools for regenerative medicine. In the field of hematology, generation of hematopoietic stem cells (HSCs) and mature hematopoietic cells (HCs) from ES and iPS cells through mesodermal cells, the ancestors of HCs, can facilitate transplantation and transfusion therapy. Several studies report generation of functional HCs from both mouse and human ES and iPS cells. This approach will likely be applied to individual patient-derived iPS cells for regenerative medicine approaches and drug screening in the future. Here, we summarize current studies of HC-generation from ES and iPS cells.

Keywords Mesoderm induction · Hematopoietic cell differentiation · ES cell · iPS cell

Abbreviations

ES Embryonic stem
iPS Induced pluripotent stem
HSC Hematopoietic stem cell

T. Inoue-Yokoo · D. Sugiyama (✉)
Division of Hematopoietic Stem Cells, Advanced Medical Initiatives, Department of Advanced Medical Initiatives, Kyushu University Faculty of Medical Sciences, Fukuoka 812-8582, Japan
e-mail: ds-mons@yb3.so-net.ne.jp

T. Inoue-Yokoo
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan

K. Tani
Department of Medical Genomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan

HPC Hematopoietic progenitor cell
HC Hematopoietic cell

Introduction

Hematopoiesis is the process by which mature and functional hematopoietic cells (HCs), such as leukocytes (granulocytes, macrophages, lymphocytes), erythrocytes and platelets, are generated from hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) to maintain homeostasis. Hematopoiesis is controlled intrinsically via transcription factors and small RNAs [1–3] and extrinsically through growth factors and extracellular matrices secreted from niche cells surrounding HCs [4–6]. Faulty regulation of hematopoiesis leads to hematological diseases, such as anemia, leukemia and lymphoma, in which HSC transplantation and/or transfusion of erythrocytes or platelets are dependent on disease status. Regardless of the HSC source (patient cells, donor cells, or cord blood cells), transplantation is a promising therapy for some hematological diseases. However, problems remain in HSC transplantation, such as donor shortages, viral contamination and graft-versus host disease. To overcome these problems, HSC generation from other cells is a possible alternative to expansion of cord blood HSCs. Mature HCs, such as erythrocytes and platelets, are obtained primarily from donors and transfused into patients with hematological diseases and under surgical operation. Likewise, use of HSCs is also associated with problems, such as shortage of donors, viral infection and rejection. Overall, the ability to generate mature HCs from other cells would guarantee a continuous supply of cells and ensure safe and efficient transfusion therapy.

To address these issues, *in vitro* HC generation from other cells, particularly from embryonic stem (ES) cells [7] and induced pluripotent stem (iPS) cells [8], has been attempted. ES cells are established from the inner cell mass of a blastocyst, maintain their pluripotent and undifferentiated status *in vitro* and differentiate into any cell type in appropriate culture conditions. Furthermore, ES cells can have pluripotency *in vivo* and form teratoma in immunodeficient mice, and can be used to generate chimeric mice *in vivo*. To understand molecular mechanisms underlying developmental processes, ES cells are frequently utilized, since they mimic *in vivo* development *in vitro* (Fig. 1). iPS cells, on the other hand are created by ectopic expression of four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) in somatic cells, such as fibroblasts, hepatocytes, gastric epithelial cells, pancreatic cells, B cells and CD34⁺ cord blood cells, and exhibit properties of pluripotent ES cells. iPS cells established from a patient's somatic cells could function as useful tools for regenerative medicine and drug screening by manipulating lineage specific differentiation *in vitro* (Fig. 1).

Here we summarize current studies relevant to generation of HCs and mesodermal cells from ES and iPS cells in both mice and humans (Table 1).

General Induction Methods

Several methods to differentiate mesodermal cells and hematopoietic cells from ES and iPS cells have been reported. They include (i) embryoid body (EB) formation, (ii) co-culture with feeder cells, and (iii) growth in extra cellular matrix-coated dishes. In the first method, undifferentiated ES and iPS cell colonies are separated into small cell pieces enzymatically or by physical dissection, following by EB formation in suspension in a culture dish or hanging drop. EBs are spherical cell aggregates that proliferate and differentiate into all three germ layers (i). Alternatively, ES or iPS cells can be seeded on OP9 stromal cells, which are established from the newborn calvaria of op-/op- mice and support HCs differentiation (ii), or seeded on collagen IV-coated dishes, which promote cell proliferation and form




Fig. 1 Generation of hematopoietic cells from pluripotent stem cells *in vitro*. Embryonic stem (ES) and induced pluripotent stem (iPS) cells have been differentiated into hematopoietic cells (HCs) through mesodermal cells, ancestors of HCs, by two methods: embryoid body (EB)

formation and co-culture with stromal cells *in vitro*. These cells are potentially applicable to regenerative medicine and drug screening by manipulating their lineage specific differentiation *in vitro*

Table 1 Generation of hematopoietic lineage from pluripotent stem cells

Species	Mouse		Human	
	ES	iPS	ES	iPS
Pluripotent stem cell				
Mesoderm	12–14	15, 16	17–20	17–20
HPC, HSC	21–23	25, 26	17, 20, 27	17, 20
Erythroid cell	28–32	25	33, 34	17–19, 35–37
Megakaryocyte	38, 39	–	41–43	44
Platelet	40	–	43	44
Macrophage	28, 43–47	48	17, 19, 35, 41	17, 19, 35
Neutrophil	49	–	18, 50, 51	52, 53
Lymphocyte	28, 54, 58, 59, 65	55, 60, 66	56, 61–63, 67	55, 67

an attachment scaffold (iii). In all cases, cell fate, directivity differentiation pattern for mesoderm and HCs differentiation is controlled by cytokines.

Mesodermal Cells

HCs are mesodermal in origin. In mammalian embryogenesis, the three germ layers, ectoderm, endoderm and mesoderm, are formed via spatiotemporal signals. Formation of the primitive streak (PS), the structure that establishes bilateral symmetry, marks the beginning of gastrulation and the emergence of mesodermal precursors. Mesoderm, derived from interaction between the endoderm and ectoderm, forms paraxial, intermediate, and lateral tissues during the mid- to late-streak stage. Among precursors in the axial, paraxial, intermediate and lateral mesoderm, blood vessels and HCs are generated from the lateral mesoderm. Therefore, the appearance of lateral mesoderm is one of indicator to hematopoietic differentiation.

One question is whether ES and iPS cell-derived cells express the surface antigen markers, such as E-cadherin (E-cad), a marker of both ectoderm and endoderm), platelet-derived endothelial growth factor receptor (PDGFR α), and Flk1 (also known as VEGF receptor 2 and a marker lateral mesoderm) [9–11] and transcription factors, such as *Tbx6* and *Brachyury* (a marker pan mesoderm) (Fig. 2).

In mouse, a high percentage of Flk1⁺ mesodermal cells are reportedly obtained from EBs around days 4 to 4.5 after ES cell differentiation [12, 13]. ES cells cultured on collagen-IV-coated dishes differentiate into Flk1⁺PDGFR α ⁺ immature mesodermal precursors, which then give rise to Flk1⁺PDGFR α ⁻ cells, which are precursor of endothelial and HCs [14]. Flk1⁺ mesodermal cells have been generated from several kinds of mouse iPS cells, such as mouse embryonic fibroblasts (MEFs), tail tip fibroblasts (TTFs), hepatocytes, and gastric epithelial cells. Among them, MEF-derived iPS cells exhibit the highest proportion of E-cad⁺Flk1⁺ cells [15]. Mesodermal potential as evaluated by the presence of E-cad⁺Flk1⁺ cells and expression of *Brachyury*, *Flk1*, and *Tbx6* mRNA vary among several iPS cell lines derived from

identical TTFs. The level of ectopically expressed and remain of c-Myc likely underlies the differences [16].

Some groups have reported mesodermal differentiation from both human ES and iPS cells. Flk1⁺CD34⁺ mesodermal progenitors were generated from KhES1, KhES3 ES cells (KhES1, KhES3) and iPS cells (201B7, 253 G4; derived from dermal fibroblasts) co-cultured with OP9 cells and cytokines [17]. Morishima et al. report that ES (KhES3) and iPS (201B6, 253 G1, 253 G4; derived from dermal fibroblasts) cells generated Flk1⁺ cells that contained hemangioblasts and Flk1^{high}CD34⁺ cells with hematopoietic potential [18]. *BRACHYURY* and *WNT3A* mRNA expression was also confirmed in ES-, iPS-, and patient iPS-derived mesodermal cells by others [19, 20].

Hematopoietic Stem (HSCs) and Progenitor (HPCs) Cells

HSCs, which top the hematopoietic hierarchy, have self-renewal capacity and multipotency, and differentiate first into the progenitors of each hematopoietic lineage, which then mature into functional cells, including leukocytes, erythrocytes and platelets. As HSCs are used for transplantation, pluripotent cell-derived HSCs could serve as a source for future clinical applications. Questions remain as to whether HPCs and HSCs derived from pluripotent cells express c-Kit, Sca-1, CD45 in mouse, or CD34 and CD45 in humans in vitro, and whether these precursors have hematopoietic repopulation capacity in vivo (Fig. 2).

In mice, Burt et al. reported a differentiation method that did not require gene modification. EB formation of ES cells treated with SCF, IL-3 and IL-6 with serum for 7–10 days yielded CD45⁺c-Kit⁺HPCs with long term (for a maximum 20 weeks) repopulation capacity, as measured by chimerism and differentiation into lymphoid and myeloid lineages after transplantation into irradiated mice [21]. However, this approach is not widespread, suggesting that success may depend on serum they used. Therefore, establishment of serum-independent culture condition would be needed to get reproducible result.




Fig. 2 Schematic diagram of pluripotent cell-derived mesodermal cells, HPCs and HSCs. ES and iPS cells-derived mesodermal cells are characterized by the expression of FLK1 (also known as VEGF receptor 2) and specific transcription factor genes (*Brachyury* and *Tbx6* in mouse; *BRACHYURY* and *WNT3A* in human). Hematopoietic progenitor cells (HPCs) and hematopoietic stem cells (HSCs)-derived from pluripotent cells are characterized by the expression of hematopoietic surface markers (c-Kit, Sca-1 and CD45 in mouse; CD34 and

CD45 in human) and specific transcription factor genes (*Runx1*, *Hoxb4*, *CD41* and *CD45* in mouse; *RUNX1*, *HOXB4*, *CD45* and *CD38* in human). In vivo transplantation assay enables us to evaluate the potential of both HPCs and HSCs. Extensive long-term reconstitution with multipotency and self-renewal capacities of all hematopoietic lineages can be observed in HSCs, whereas short and/or relatively long-term reconstituting in HPCs can give rise to certain lineages

On the other hand, to promote the development and expansion of ES cell-derived HSCs, genetically-modified methods have been reported. Kyba et al. reported that forced expression of HoxB4 in immature ES cell-derived HPCs conferred definitive hematopoietic potential in mouse ES cells [22]. Temporal induction of HoxB4 during the course of EB formation increased the number of immature HPCs in vitro. In addition, HoxB4-induced ES-derived HPCs engrafted and produced lymphoid and myeloid cells in both primary (for a maximum 12 weeks) and secondary (for a maximum of 20 weeks) transplanted mice [22]. Combined ectopic expression of HoxB4 and Cdx4, which is also homeobox transcription factor, resulted in more efficient reconstitution than HoxB4 alone [23]. Unlike the case in mouse, a high incidence of leukemia occurred after transducing a *HOXB4*-expressing retroviral vector in large animals, such as dog and monkey [24], suggesting that care should be taken using gene-manipulation methods for HSC transplantation.

The HoxB4-constitutive transduction method is also effective to establish mouse iPS cells from fibroblasts in a sickle cell anemia model. Resulting iPS cell-derived progenitors grown in the presence of OP9 stromal cells reconstituted the hematopoietic system after transplantation into irradiated mice [25]. Lin et al. has reported a hematopoietic differentiation culture method for iPS cells established from MEFs, which lacks a feeder cell layer or gene manipulation. After 7 days of culture with “conditioned medium”, EBs prepared from culture of OP9-DL1 cells (modified OP9 cells expressing the delta-like 1 (DL1) Notch ligand) generated c-Kit⁺Sca1⁺HPCs that could differentiate along the myeloid lineage [26]. It has not yet been examined whether HPCs derived from this method could reconstitute in vivo.

Unlike the case in mouse, ectopic expression of HoxB4 temporarily enhanced generation and proliferation of human HPCs in vitro but did not promote a significant increase in the number of HSCs in vitro and had no effect on repopulating capacity of HSCs in immuno-deficient mice [27]. This